...
首页> 外文期刊>Molecular pharmaceutics >Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods
【24h】

Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods

机译:短暂的过饱和支持脂质的制剂的药物吸收短时间,但需要持续的溶解来进行更长的吸收时段

获取原文
获取原文并翻译 | 示例
           

摘要

The current studies sought to explore the impact of drug supersaturation and precipitation during the dispersion and digestion of lipid-based formulations (LBFs), on in vivo absorption using a coupled in vitro digestion in vivo perfusion absorption model. Fenofibrate absorption was evaluated from a number of LBFs with different solubilization and supersaturation capacities, and conditions at the absorptive membrane manipulated by changing perfusion conditions, intestine segment lengths, and by the conduct of experiments in the presence or absence of suspended/precipitated drug. LBF dispersion and digestion resulted in varying periods of supersaturation across the different formulations. Even fleeting (5-10 min) periods of supersaturation were able to drive flux across a perfused 10 cm intestinal segment for up to 60 min, although over longer infusion periods (60-80 min) flux dropped in the absence of ongoing drug solubilization and supersaturation. In contrast, the presence or absence of precipitated/suspended drug, had little impact on drug flux. When perfused intestinal segment lengths were extended, the role of initial supersaturation was attenuated and ongoing solubilization conditions became the primary driver of absorptive flux. The data suggest that for highly permeable drugs such as fenofibrate, a short period of supersaturation at the absorptive membrane may be sufficient to drive absorptive drug flux in spite of significant drug precipitation on formulation dispersion or digestion in vitro. In contrast, where longer periods of absorption are required, for example, at higher doses, the requirement for ongoing solubilization and supersaturation becomes more apparent.
机译:目前的研究试图探讨药物过饱和度和沉淀在脂质基制剂(LBFS)的分散和消解过程中的影响,在体内灌注吸收模型中的体外消化中的体外消化中的体内吸收。在具有不同溶解和超饱和能力的LBF中评价非诺比纤维的吸收,并且通过在存在或不存在悬浮/沉淀的药物的情况下进行实验,通过在存在或不存在的实验中进行吸收膜的条件。 LBF分散和消化导致不同配方中的过饱和时期的变化。即使是呼出(5-10分钟)的超饱和时期都能够在灌注10cm肠道段中驱动通量,长达60分钟,尽管在没有持续的药物溶解的情况下,过度的输注时期(60-80分钟)势下降过饱和。相比之下,对沉淀/悬浮药的存在或不存在对药物通量影响很小。当延长灌注肠道段长度时,初始过饱和度的作用衰减,并且持续的溶解条件成为吸收通量的主要驱动器。该数据表明,对于诸如非诺纤维的高渗透性药物,尽管在体外配方分散或消化的显着药物沉淀,但吸收膜在吸收膜处的过饱和的短时间可能足以推动吸收性药物通量。相反,需要更长的吸收时期,例如,在更高的剂量下,持续溶解和过饱和的要求变得更加明显。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号